Impact of established cardiovascular disease on 10-year death after coronary revascularization for complex coronary artery disease — Rutao Wang (2021) | RDL Network
Impact of established cardiovascular disease on 10-year death after coronary revascularization for complex coronary artery disease
Clinical Research in Cardiology 110(10): 1680-1691
Article 2021 English
Authors
RW
Rutao Wang
SG
Scot Garg
CG
Chao Gao
Abstract
1 min read
Aims To investigate the impact of established cardiovascular disease (CVD) on 10-year all-cause death following coronary revascularization in patients with complex coronary artery disease (CAD). Methods The SYNTAXES study assessed vital status out to 10 years of patients with complex CAD enrolled in the SYNTAX trial. The relative efficacy of PCI versus CABG in terms of 10-year all-cause death was assessed according to co-existing CVD. Results Established CVD status was recorded in 1771 (98.3%) patients, of whom 827 (46.7%) had established CVD. Compared to those without CVD, patients with CVD had a significantly higher risk of 10-year all-cause death (31.4% vs. 21.7%; adjusted HR: 1.40; 95% CI 1.08–1.80, p = 0.010). In patients with CVD, PCI had a non-significant numerically higher risk of 10-year all-cause death compared with CABG (35.9% vs. 27.2%; adjusted HR: 1.14; 95% CI 0.83–1.58, p = 0.412). The relative treatment effects of PCI versus CABG on 10-year all-cause death in patients with complex CAD were similar irrespective of the presence of CVD ( p -interaction = 0.986). Only those patients with CVD in ≥ 2 territories had a higher risk of 10-year all-cause death (adjusted HR: 2.99, 95% CI 2.11–4.23, p < 0.001) compared to those without CVD. Conclusions The presence of CVD involving more than one territory was associated with a significantly increased risk of 10-year all-cause death, which was non-significantly higher in complex CAD patients treated with PCI compared with CABG. Acceptable long-term outcomes were observed, suggesting that patients with established CVD should not be precluded from undergoing invasive angiography or revascularization. Trial registration SYNTAX : ClinicalTrials.gov reference: NCT00114972. SYNTAX Extended Survival : ClinicalTrials.gov reference: NCT03417050. Graphic abstract
Masafumi Ono, Patrick W. Serruys, Hironori Hara, Hideyuki Kawashima, Chao Gao, Rutao Wang, Kuniaki Takahashi, Neil O’Leary, Joanna J. Wykrzykowska, Faisal Sharif, Jan J. Piek, Scot Garg, Michael J. Mack, David R. Holmes, Marie‐Claude Morice, Stuart J. Head, A. Pieter Kappetein, Daniel J.F.M. Thuijs, Thilo Noack, Piroze Davierwala, Friedrich W. Mohr, David J. Cohen, Yoshinobu Onuma
Rutao Wang, Patrick W. Serruys, Chao Gao, Hironori Hara, Kuniaki Takahashi, Masafumi Ono, Hideyuki Kawashima, Neil O’Leary, David R. Holmes, Adam Witkowski, Nick Curzen, Francesco Burzotta, Stefan James, Robert‐Jan van Geuns, A. Pieter Kappetein, Marie‐Angèle Morel, Stuart J. Head, Daniel J.F.M. Thuijs, Piroze Davierwala, Timothy O’Brien, Valentı́n Fuster, Scot Garg,
Rutao Wang, Mattia Lunardi, Hironori Hara, Chao Gao, Masafumi Ono, Piroze Davierwala, David R. Holmes, Friedrich W. Mohr, Nick Curzen, Francesco Burzotta, Robert‐Jan van Geuns, A. Pieter Kappetein, Stuart J. Head, Daniel J.F.M. Thuijs, Ling Tao, Scot Garg, Yoshinobu Onuma, William Wijns, Patrick W. Serruys
Rutao Wang, Mattia Lunardi, Hironori Hara, Chao Gao, Masafumi Ono, Piroze Davierwala, Robert‐Jan van Geuns, A. Pieter Kappetein, Stuart J. Head, Daniel J.F.M. Thuijs, Ling Tao, Scot Garg, Yoshinobu Onuma, William Wijns, Patrick W. Serruys
Discussion(0)
No comments yet. Be the first to comment.